Interim safety analysis of a phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC) Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Garon, EB
  • Sadeghi Hosseini, Seyed Saman
  • Kabbinavar, FF
  • Reckamp, KL
  • Marquez-Garban, DC
  • Stabile, LP
  • Goodglick, L
  • Dubinett, SM
  • Siegfried, JM
  • Pietras, RJ

publication date

  • May 20, 2008